Piper Jaffray Companies restated their overweight rating on shares of Vericel (NASDAQ:VCEL) in a research report released on Tuesday, The Fly reports. Piper Jaffray Companies currently has a $9.00 price target on the biotechnology company’s stock.
Several other analysts have also recently issued reports on VCEL. BTIG Research reaffirmed a buy rating and set a $6.00 target price on shares of Vericel in a research report on Thursday, September 7th. ValuEngine cut Vericel from a hold rating to a sell rating in a research report on Friday, December 1st.
Vericel (NASDAQ:VCEL) opened at $5.85 on Tuesday. The company has a current ratio of 2.50, a quick ratio of 2.22 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $192.02, a price-to-earnings ratio of -6.65 and a beta of 3.02. Vericel has a fifty-two week low of $2.25 and a fifty-two week high of $6.30.
A number of hedge funds and other institutional investors have recently made changes to their positions in VCEL. Bank of New York Mellon Corp boosted its position in Vericel by 13.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 37,202 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 4,523 shares in the last quarter. First Washington CORP acquired a new stake in shares of Vericel in the 2nd quarter worth $2,230,000. Vanguard Group Inc. boosted its position in shares of Vericel by 7.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,212,799 shares of the biotechnology company’s stock worth $4,002,000 after purchasing an additional 88,645 shares in the last quarter. Archon Capital Management LLC acquired a new stake in shares of Vericel in the 2nd quarter worth $4,412,000. Finally, Perkins Capital Management Inc. boosted its position in shares of Vericel by 118.4% in the 3rd quarter. Perkins Capital Management Inc. now owns 562,600 shares of the biotechnology company’s stock worth $3,376,000 after purchasing an additional 305,000 shares in the last quarter. 33.12% of the stock is currently owned by institutional investors and hedge funds.
Vericel Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
What are top analysts saying about Vericel? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vericel and related companies.